Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) („Corbus” or the „Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2016. Read more >>